Henry Ford Health

Henry Ford Health Scholarly Commons

Diagnostic Radiology Articles

Diagnostic Radiology

11-9-2021

An Image Quality-informed Framework for CT Characterization

Rebecca Smith-Bindman

Sophronia Yu

Yifei Wang

Marc D. Kohli

Philip Chu

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/radiology_articles

Recommended Citation

Smith-Bindman R, Yu S, Wang Y, Kohli MD, Chu P, Chung R, Luong J, Bos D, Stewart C, Bista B, Alejandrez Cisneros A, Delman B, Einstein AJ, Flynn M, Romano P, Seibert JA, Westphalen AC, and Bindman A. An Image Quality-informed Framework for CT Characterization. Radiology 2021; 210591.

This Article is brought to you for free and open access by the Diagnostic Radiology at Henry Ford Health Scholarly Commons. It has been accepted for inclusion in Diagnostic Radiology Articles by an authorized administrator of Henry Ford Health Scholarly Commons.

Authors							
becca Smith-Bindman, Sophronia Yu, Yifei Wang, Marc D. Kohli, Philip Chu, Robert Chung, Jason Luon nise Bos, Carly Stewart, Biraj Bista, Alejandro Alejandrez Cisneros, Bradley Delman, Andrew J. Einstei chael Flynn, Patrick Romano, J. Anthony Seibert, Antonio C. Westphalen, and Andrew Bindman							



An Image Quality-informed Framework for CT Characterization

Rebecca Smith-Bindman, MD • Sophronia Yu, MPH • Yifei Wang, PhD • Marc D. Kohli, MD • Philip Chu, MS • Robert Chung, PhD • Jason Luong, MS • Denise Bos, MD • Carly Stewart, MHA • Biraj Bista, MD • Alejandro Alejandrez Cisneros, BS • Bradley Delman, MD • Andrew J. Einstein, MD, PhD • Michael Flynn, PhD • Patrick Romano, MD • J. Anthony Seibert, PhD • Antonio C. Westphalen, MD • Andrew Bindman, MD

From the Department of Radiology and Biomedical Imaging (R.S.B., S.Y., Y.W., M.D.K., P.C., R.C., J.L., C.S.), Department of Epidemiology and Biostatistics (R.S.B., A.B.), Philip R. Lee Institute for Health Policy Studies (R.S.B., A.B.), and Department of Medicine (A.B.), University of California San Francisco (UCSF), UCSF Mission Bay Campus, Mission Hall: Global Health and Clinical Sciences Building, 550 16th St, 2nd Floor, Box 0560, San Francisco, CA 94158; Department of Demography, University of California Berkeley, Berkeley, Calif (R.C.); Institute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Germany (D.B.); Department of Radiology and Biomedical Imaging, University of California Irvine, Irvine, Calif (B.B.); UCSF Medical School, San Francisco, Calif (A.A.C.); Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (B.D.); Seymour, Paul, and Gloria Milstein Division of Cardiology, Department of Medicine, and Department of Radiology, Columbia University Irving Medical Center and New York—Presbyterian Hospital, New York, NY (A.J.E.); Department of Radiology and Public Health Sciences, Henry Ford Health System, Detroit, Mich (M.F.); Department of Nuclear Engineering and Radiological Science, University of Michigan, Ann Arbor, Mich (M.F.); Department of Medicine and Pediatrics (P.R.) and Department of Radiology (J.A.S.), University of California Davis Health, Sacramento, Calif; and Department of Radiology, University of Washington, Seattle, WA (A.C.W.) Received March 24, 2021; revision requested May 19; revision received August 12; accepted September 1. Address correspondence to R.S.B. (e-mail: rebecca.smith-bindman@ucsf.edu).

Supported by the National Institutes of Health (grant no. R01-CA181191), Patient-Centered Outcomes Research Institute (grant nos. CD-1304-7043 and DI-2018C1-11375), and Centers for Medicare and Medicaid Services (grant no. 1V1CMS331638).

Conflicts of interest are listed at the end of this article.

See also the editorial by Mahesh in this issue.

Radiology 2021; 000:1–10 ● https://doi.org/10.1148/radiol.2021210591 ● Content codes: CT SQ

Background: Lack of standardization in CT protocol choice contributes to radiation dose variation.

Purpose: To create a framework to assess radiation doses within broad CT categories defined according to body region and clinical imaging indication and to cluster indications according to the dose required for sufficient image quality.

Materials and Methods: This was a retrospective study using Digital Imaging and Communications in Medicine metadata. CT examinations in adults from January 1, 2016 to December 31, 2019 from the University of California San Francisco International CT Dose Registry were grouped into 19 categories according to body region and required radiation dose levels. Five body regions had a single dose range (ie, extremities, neck, thoracolumbar spine, combined chest and abdomen, and combined thoracolumbar spine). Five additional regions were subdivided according to dose. Head, chest, cardiac, and abdomen each had low, routine, and high dose categories; combined head and neck had routine and high dose categories. For each category, the median and 75th percentile (ie, diagnostic reference level [DRL]) were determined for dose-length product, and the variation in dose within categories versus across categories was calculated and compared using an analysis of variance. Relative median and DRL (95% CI) doses comparing high dose versus low dose categories were calculated.

Results: Among 4.5 million examinations, the median and DRL doses varied approximately 10 times between categories compared with between indications within categories. For head, chest, abdomen, and cardiac (3 266 546 examinations [72%]), the relative median doses were higher in examinations assigned to the high dose categories than in examinations assigned to the low dose categories, suggesting the assignment of indications to the broad categories is valid (head, 3.4-fold higher [95% CI: 3.4, 3.5]; chest, 9.6 [95% CI: 9.3, 10.0]; abdomen, 2.4 [95% CI: 2.4, 2.5]; and cardiac, 18.1 [95% CI: 17.7, 18.6]). Results were similar for DRL doses (all P < .001).

Conclusion: Broad categories based on image quality requirements are a suitable framework for simplifying radiation dose assessment, according to expected variation between and within categories.

© RSNA, 2021

Radiation doses for CT are highly variable across patients and institutions (1). Although some of this variation reflects hardware characteristics and appropriate differences because of patient factors such as size and clinical indication for imaging, most of the variation stems from provider choices in how CT is performed (2). The protocols used in CT are not standardized according to clinical indications across locations or even among providers within the same location. Thus, protocol decisions affect considerably the amount of radiation patients receive during CT scanning (2,3). Radiologists, medical

physicists, and professional organizations have made considerable efforts to standardize protocols (4–8), yet large variations in radiation dose persist (2,9).

Excessive radiation from undergoing multiple or higherdose CT examinations may be associated with increased cancer risk (10,11); thus, reducing radiation whenever possible is beneficial to the patient. Because the amount of radiation needed for adequate image quality varies according to anatomic region and clinical indication, what constitutes an excessive radiation dose will also vary according to anatomic region and clinical indication.

This copy is for personal use only. To order printed copies, contact reprints@rsna.org

Abbreviations

 $CTDI_{vol}$ = volume CT dose index, DLP = dose-length product, DRL = diagnostic reference level

Summary

A framework that assigns CT examinations into broad categories based on body region and image quality requirements simplifies assessment of radiation dose for benchmarking and for developing CT protocols.

Key Results

- Based on 4.5 million CT examinations grouped into 19 categories according to body region and expected image quality requirements, radiation doses varied approximately 10 times between categories compared with between indications within categories (P < .001), meaning the categories are valid.
- Radiation doses were significantly higher for examinations assigned to the high versus low radiation dose category; for example, 3.4-fold higher for head; 9.6 for chest; 18.1 for cardiac; and 2.4 for abdomen.
- Approximately 91% (4129165 examinations) of diagnostic CT examinations can be assigned to one of the 19 categories; three categories—routine head, routine chest, and routine abdomen—account for 67% (2796365 examinations) of total examinations.

One approach to aid in the selection and assessment of CT radiation doses is the publication of benchmarks that clinicians can use when making local choices for how to scan patients. The most commonly used benchmarks are created according to protocol, such as single-phase and multiple-phase abdomen CT (1). The primary challenge in using a protocol-based approach for setting benchmarks is that there is little consensus or consistency in how patients are assigned to protocol. Therefore, assessing radiation doses at a facility using only information from protocols can lead to misleading results, as protocol choice is at the discretion of the radiologist and is a key determinant of quality. Stratifying according to that choice eliminates the ability to form a judgment about this important component of quality. Furthermore, imaging facilities often create customized sets of protocols, and the idiosyncratic nature of such protocols makes comparisons difficult across sites.

To simplify evaluation of radiation doses, we developed a framework that assigns CT examinations into 19 broad categories based on body region and clinical indication, where we grouped indications that have similar image quality requirements into the same category. These 19 categories capture the vast majority of reasons why patients undergo CT, and the use of these categories can aid in benchmarking. We used data from a large CT registry to assess the content validity of our approach by examining actual radiation doses within and across categories.

Materials and Methods

Registry and Collaborating Institutions

The University of California San Francisco International CT Dose Registry includes CT examination data captured from 161 hospitals or imaging facilities across seven countries. The registry is smaller than, but broadly similar to, the larger American College of Radiology Dose Index Registry (12). Although both registries focus on dose optimization, a defining purpose of the

University of California San Francisco registry has been to assess radiation dose delivered across a global range of facilities and to use these data to develop and study the impact of interventions to improve the safety of CT. The data are captured in a manner compliant with the Health Insurance Portability and Accountability Act using dose management software (Radimetrics, Bayer) and have been used previously to describe factors associated with radiation dose levels, in the context of a randomized controlled trial (2,13). The institutional review boards at the lead and collaborating institutions approved the study, relied on the lead institution's approval, or considered the study exempt human subjects research.

Study Population

Drawing from the registry, we retrospectively analyzed consecutive diagnostic CT examinations performed from January 1, 2016, to December 31, 2019, in patients aged 18 years and older. Data were derived from 383 scanners, including 74 models from the four largest manufacturers—GE Healthcare, Philips, Siemens, and Canon Medical Systems.

Image Quality-informed Framework for CT Categories

Because different parts of the body require different amounts of radiation to create images sufficient for diagnosis, the framework first relies on categorizing CT examinations into 10 body regions. In five of these regions (ie, extremities, neck [which includes cervical spine], thoracolumbar spine [reflecting either thoracic spine or lumbar spine], combined chest and abdomen, and combined thoracolumbar spine [reflecting both thoracic and lumber spine]), clinical indications for scanning do not play a substantial role in altering the amount of radiation needed; thus, there is a single category for each of these body regions. In five other body regions (ie, head, chest, cardiac, abdomen, and combined head and neck), clinical indications affect the optimal radiation dose to achieve differing image quality requirements, and CT examinations were divided based on clinical indications into stand-alone low, routine, or high dose categories (Table 1). The approach to determining low, routine, or high radiation doses within these categories was informed by the following: (a) a review of the published literature; (b) consultation with radiologists with specialty expertise; (c) input from a technical expert panel assembled in relation to the creation of a CT quality measure for the Centers for Medicare and Medicaid Services; and (d) empirical evaluation of 4.5 million consecutive CT examinations, described herein (14).

We constructed the CT categories based on perceived image quality requirements, which have face validity as assessed by the technical expert panel (14). For example, the image quality required to observe a small, well-defined structure such as a lung nodule surrounded by air is less than the quality needed to study the margins of a mass adjacent to other organs when assessing the extent of a lung cancer. Thus, these indications are included in different CT categories—low dose chest and routine dose chest, respectively. There were no direct image quality assessments made as part of this research.

The emphasis in creating the CT categories was to identify indications that were exceptions to the routine dose

Radiation Dose Level	Indications for Head Imaging	Indications for Chest Imaging	Indications for Cardiac Imaging	Indications for Abdomen Imaging
Low dose	Facial skeleton; sinus; bone; ventricular shunt	Lung cancer screening; lung nodule surveillance		Colon cancer screening; renal stones (known or suspected); bladder (without contrast material)
Routine dose	Suspected hemorrhage (stroke); trauma	Angiography; cancer;* interstitial lung disease; pulmonary embolism; trauma; high resolution	Angiography, coronary	Abscess; angiography; gastrointestinal tract evaluation, enterography;† liver (not otherwise specified); trauma
High dose	Perfusion angiography	Dissection	Transcatheter aortic valve replacement	Abdominal run-off; acute gastrointestinal bleeding; adrenal nodule; angiography for aortic injury; biliary cancer; bladder cystography (with contrast material); fistula; hepatocellular cancer; metastatic cancer; pancreas (pancreatic cancer); renal mass (hematuria or cancer); transplant (donor, recipient, or postoperative); urography

Note.—These listed diagnoses are usually suspected, not confirmed, at the time of imaging.

category, rather than to identify every indication for scanning within the routine category. For example, imaging of facial bones for a suspected fracture would require a lower radiation dose, whereas imaging of brain tissue to assess perfusion related to a suspected stroke would require a higher radiation dose, compared with the routine dose head category. The requirement for multiphase scanning was an important consideration for assigning indications to high dose categories. Combining the five categories with a single radiation dose range, the four regions subcategorized as low, routine, or high dose, and the routine and high dose for combined head and neck categories resulted in 19 total categories. The body region and clinical indication for each CT examination in the registry was determined using natural language processing applied to text strings in the Digital Imaging and Communications in Medicine metadata, including the study description and protocol name.

The method of using the Digital Imaging and Communications in Medicine metadata to assign CT examinations to the 19 CT categories was validated by comparing this approach to a determination based on a detailed chart review. Full medical records, including physician notes, laboratory and pathologic results, and ordering indication, were abstracted by a radiology technologist to create the reference standard CT category assignment for a randomly selected sample of 1102 patients who underwent CT at a single health system. The CT category derived from Digital Imaging and Communications in Medicine metadata was correct for 911 of the 1012 scans (90%).

Radiation Dose

CT scanners report radiation dose metrics derived from acquisition parameters that correlate closely with absorbed dose and imparted energy, and from which these variables can be estimated. These scanner-reported metrics are herein referred to as "radiation dose." The radiation dose for each CT examination includes all irradiating events that were part of that examination. Two radiation dose metrics are reported—volume CT dose index (CTDI...) in milligray and dose-length product (DLP) in milligray-centimeter. DLP values were summed across all irradiating events to generate scanninglevel DLP, and CTDI, was a mean weighted according to scanning length. All analyses are adjusted for patient size using the midscanning water-equivalent diameter (15). The analyses did not adjust for phantom, as CT examinations in the registry had virtual uniformity in phantom selection by body region. The diagnostic reference level (DRL) was defined as the 75th percentile of the observed distribution of size-adjusted CTDI_{vol} and DLP.

Statistical Analysis

For each CT category, the scanning frequency and the median and DRL in radiation dose for CTDI $_{\rm vol}$ and DLP were calculated. For the head, chest, cardiac, and abdomen categories, we compared mean doses between low and high dose categories using analysis of variance and estimated ratios of the median radiation doses, with 95% CIs, after adjusting for patient size. P < .05 was considered a statistically significant difference.

^{*} Cancer includes evaluation for suspected cancer, staging of known cancer, and evaluation for suspected metastatic disease.

[†] Gastrointestinal tract symptoms include abdominal pain, weight loss, nausea, vomiting, and diarrhea.

[‡] Angiography for aortic injury includes assessment for rupture, dissection, and endovascular leak.

[§] High radiation dose for abdomen imaging includes evaluation for suspected cancer symptoms, cancer staging, and evaluation for metastatic disease in the liver, pancreas, biliary system, peritoneum, breast, kidney, adrenal gland, bladder, or unknown primary tumor.

For each indication within the head, chest, abdomen, and cardiac low, routine, and high dose categories, the CTDI_{vol} versus DLP was graphed showing 25th, 50th, and 75th percentiles. Two sets of analysis of variance analyses were conducted with size-adjusted DLP as the outcome variable. Analysis of variance uses F tests to statistically test the equality of means. The F statistic is a ratio of two variances (ie, a measure of dispersion). First, we assessed whether the radiation dose varied according to clinical indications within each category. A finding that radiation doses were strongly associated with clinical indications within a category would suggest that the determination of indication for each examination was accurate. Second, we compared the variation in radiation doses within a category (eg, low dose head) with the variation in doses across categories within the same body region (eg, low, routine, and high dose head). A finding of greater variation across categories within a body region than that within the categories of that body region would suggest the assignment of clinical indications to the low, routine, or high dose category is appropriate. R software (version 3.6.3, R Foundation for Statistical Computing) was used for all analyses.

Results

Approximately 4.5 million CT examinations were included (Table 2). Overall, 80.9% of the examinations (3671128) were from the United States. The 19 categories capture approximately 91.0% of CT examinations (4129165) in the registry during the testing period. The number of CT examinations performed for each age group increased with age up to 70 years. The body regions of head, chest, and abdomen comprised 71.9% (3 266 546) of total CT examinations. Within these three body regions, the routine category accounted for 67% of examinations (2796365) (83.4% of head examinations [1 040 518], 94.8% of chest examinations [753 583], and 86.2% of abdominal examinations [1002264]). As a result, around six in 10 CT examinations were in the categories of routine dose abdomen, routine dose head, or routine dose chest (Table 3). The median and DRL for DLP and CT-DI_{vol} were significantly different across the 19 categories (P < .001 for all analysis of variance values).

DLP Findings

Next, we assessed the DLP and $\mathrm{CTDI}_{\mathrm{vol}}$ to determine whether there were differences in radiation doses across different CT categories. Within the head, chest, abdomen, and cardiac body regions, the median and DRL radiation doses for DLP were significantly different across the low, routine, and high dose categories (P < .001 for all) (Table 3, Fig 1). For

Table 2: Characteristics of Included Patients and CT Examinations						
	No. of CT Examinations					
Characteristic	(n = 4537341)					
Time period						
January 1, 2016–December 31, 2016	1 265 334 (27.9)					
January 1, 2017–December 31, 2017	1 259 131 (27.8)					
January 1, 2018–December 31, 2018	1 131 946 (24.9)					
January 1, 2019–December 31, 2019	853 398 (18.8)					
Missing	27 532 (0.6)					
Country						
Germany	112 956 (2.5)					
Israel	318 293 (7.0)					
Japan	92 845 (2.0)					
Netherlands	88 321 (1.9)					
Switzerland	116 594 (2.6)					
United Kingdom	109 672 (2.4)					
United States	3 671 128 (80.9)					
Missing	27 532 (0.6)					
Age (y)						
18–29	351 104 (7.8)					
30–39	385 733 (8.6)					
40–49	527 455 (11.7)					
50–59	806 853 (17.9)					
60–69	956631 (21.2)					
70–79	802 601 (17.8)					
80–89	476 108 (10.6)					
90 and older	203 324 (4.5)					
Missing	35 989 (0.8)					
Sex						
F	2316913 (51.4)					
M	2 152 643 (47.9)					
Other	29 140 (0.6)					
Unknown	2656 (<0.1)					
Missing	27 532 (0.6)					
Scanner manufacturer						
Canon	414 408 (9.1)					
General Electric	1 900 558 (41.9)					
Philips	874 142 (19.3)					
Siemens	1 294 716 (28.5)					
Missing	53 517 (1.2)					
Body region						
Head	1 243 712 (27.4)					
Neck	262 037 (5.8)					
Chest	798 780 (17.6)					
Cardiac	60 381 (1.3)					
Abdomen	1 163 673 (25.6)					
Thoracolumbar spine	141 043 (3.1)					
Extremity	96 548 (2.1)					
Combined chest and abdomen	260 090 (5.7)					
Combined head and neck	98 184 (2.2)					
Combined thoracolumbar spine	4717 (0.1)					
Missing, unidentified, or other combined body regions	408 176 (9.0)					
Note.—Data are numbers of examinations, w	ith percentages in parentheses.					

		50th Percentile in Radiation Dose for DLP		75th Percentile in Radiation Dose for DLP		50th Percentile in Radiation Dose for CTDI _{vol}		75th Percentile in Radiation Dose for CTDI _{vol}	
Location and Dose	No. of Examinations	Dose (mGy · cm)	Relative Dose*	Dose (mGy · cm)	Relative Dose*	Dose (mGy · cm)	Relative Dose*		Relative Dose*
Head									
Low dose	143 093 (3.5)	375	NA	622	NA	20	NA	31	NA
Routine dose	1040518 (25.2)	852	NA	1050	NA	45	NA	55	NA
High dose	60 101 (1.5)	1280	3.4 (3.4, 3.5)	1866	3.0 (3.0, 3.0)	94	4.8 (4.8, 4.87)	150	4.8 (4.7, 4.8)
Chest	, ,								
Low dose	43 202 (1.0)	85	NA	111	NA	2	NA	3	NA
Routine dose	753 583 (18.3)	347	NA	556	NA	9	NA	13	NA
High dose	1995 (>0.1)	813	9.6 (9.3, 10.0)	1243	11.2 (10.8, 11.7)	12	4.9 (4.7, 5.1)	17	5.5 (5.3, 5.6
Abdomen	, , ,								
Low dose	77 464 (1.9)	508	NA	768		9	NA	14	NA
Routine dose	1002264 (24.3)	657	NA	1063	NA	11	NA	17	NA
High dose	83945 (2.0)	1237	2.4 (2.4, 2.5)	1926	2.5 (2.5, 2.5)	10	1.1 (1.1, 1.2)	15	1.1 (1.1, 1.1
Cardiac									
Low dose	17 164 (0.4)	82	NA	112	NA	6	NA	7	NA
Routine dose	39031 (0.9)	350	NA	743	NA	11	NA	23	NA
High dose	4186 (0.1)	1481	18.1 (17.7, 18.6)	2217	19.8 (19.1, 20.4)	24	4.0 (3.8, 4.2)	54	6.2 (6.1, 6.3
Location									
Neck	262 037 (6.3)	409	NA	612	NA	16	NA	21	NA
Thoracolumbar spine	141 043 (3.4)	753	NA	1055	NA	21	NA	30	NA
Extremity	96548 (2.3)	299	NA	588	NA	10	NA	18	NA
Combination									
Chest and abdomen	260 090 (6.3)	768	NA	1261	NA	10	NA	15	NA
Head and neck routine	88,106 (2.1)	957	NA	1309	NA	21	NA	32	NA
Head and neck high	10078 (0.2)	2547	NA	3646	NA	145	NA	25	NA
Thoracolumbar spine	4717 (0.1)	807	NA	1234	NA	16	NA	20	NA

Note.—Except where indicated, data are numbers of examinations, with percentages in parentheses. P < .001 for all. For head, chest, abdomen, and cardiac, relative radiation dose and 95% CIs for the high dose versus low dose category are provided. Fiftieth percentile is the median, and 75th percentile is the diagnostic reference level. Examinations with unknown CT categories (ie, missing, unidentified, or other combined body regions) were not included in this Table. CTDI_{vol} = volume CT dose index, DLP = dose-length product, NA = not applicable.

example, for head, the median DLP was 375 mGy \cdot cm for low dose, 852 mGy \cdot cm for routine dose, and 1280 mGy \cdot cm for high dose (difference between categories, P < .001). Within these body regions, the relative radiation doses between the high dose versus low dose categories were significantly different, which suggests the assignment of the indications to the low, routine, and high dose categories was appropriate, thus validating the categories. For median DLP, these ratios were 3.4 (95% CI: 3.4, 3.5) for head; 9.6 (95% CI: 9.3, 10.0) for chest; 2.4 (95% CI: 2.4, 2.5) for abdomen; and 18.1 (95% CI: 17.7, 18.6) for cardiac (all P < .001). For DRL DLP, these ratios were similar. Taken together, the finding of large differ-

ences in radiation doses across the different categories suggests that the assignment of specific clinical indications to each category is appropriate.

CTDI Findings

As with DLP, the median and DRL CTDI $_{vol}$ were higher within each body region for the high dose compared with the low dose categories (Table 3, Fig 1). For example, for head CT, the median CTDI $_{vol}$ was 20 mGy for low dose, 45 mGy for routine dose, and 94 mGy for high dose (difference between categories, P < .001). The ratio of median radiation doses using CTDI $_{vol}$ was 4.8 (95% CI: 4.8, 4.8) for head; 4.9 (95% CI: 4.7, 5.1) for

^{*} Numbers in parentheses are 95% CIs.




Figure 1: Box plots show distribution of dose-length product (DLP) and volume CT dose index (CTDI_{vel}) for each CT category. Box edges indicate 25th and 75th percentiles. Thick vertical line indicates median. C = cervical, L = lumbar, T = thoracic.

chest; 1.1 (95% CI: 1.1, 1.2) for abdomen; and 4.0 (95% CI: 3.8, 4.2) for cardiac.

Clinical Indications

 $\mathrm{CTDI}_{\mathrm{vol}}$ and DLP associated with specific indications that contributed to the head, chest, abdomen, and cardiac CT categories are shown in Table 4, and the $\mathrm{CTDI}_{\mathrm{vol}}$ and DLP of each indication are shown in Figure 2. Head, chest, and cardiac imaging had relatively clear separation in DLP across the subcategories (Fig 2). Abdominal imaging showed more overlap between subcategories. Taken together, although these four body regions exhibit variation in radiation doses based on clinical indications within each CT category (Tables 4, 5), the variation was far greater between CT categories than within categories (Figure 2).

Discussion

We described a framework to assign diagnostic CT examinations into broad categories based on a combination of body region and clinical indications. The distribution of study types, in particular those of the head, chest, and abdomen, is similar to the recent U.S. National Council on Radiation Protection and Measurements Report 184 (12). Within the head, chest, abdomen, and cardiac body regions, the median and diagnostic

reference level radiation doses for volume CT dose index (CT-DI and dose-length product (DLP) were significantly different across the low, routine, and high dose categories. The larger differences in CTDI, and DLP between categories in comparison to within categories validates the 19 categories. The proposed 19 categories offer a simplified and valid alternative for assessing radiation dose in comparison to protocol-specific benchmarking widely in use (1). The finding of large differences in both CTDI, and DLP across the different categories suggests that the assignment of specific clinical indications to each category is appropriate. We found larger differences between categories within body regions using DLP than in those using CTDI_{vol}. This was expected, as the indications were categorized according to the total expected radiation dose and not according to the average dose per rotation. For many high dose categories, the higher dose is the result of multiphase scanning rather than a higher dose per rotation.

The purpose of this framework is not to provide benchmark doses according to indication or category, but it may yield guidance for standardizing protocols, assigning patients to the appropriate protocol, and assessing whether a facility's radiation doses are appropriate relative to image quality requirements. Three categories—routine dose head (1040518 examinations), routine

Low dose	CT Category and Indication	No. of Examinations	CTDI _{vol} *	DLP*
Sima 55190 17 (11–22) 262 (167–383) Temporal bone 13628 38 (29–55) 417 (29–383) Ventricular shunt 30 18 (18–18) 386 (368–408) Facial skeleton 74.245 21 (14–32) 531 (310–716) Routine dose 300 46 (32–53) 891 (778–1066) Head, routine or not otherwise specified 970080 45 (37–55) 881 (688–1048) Trauma 47412 45 (40–52) 851 (761–1085 High dose 8 Fertission angiography 60 101 94 (55–150) 1280 (751–1866 Clest 1 18 (20–2) 85 (62–111) 1280 (751–1866 Clest 1 18 (20–2) 2 (2–3) 85 (62–111) Routine dose 8 18 (5–12) 303 (176–504) Clest, routine or not otherwise specified 492726 8 (5–12) 303 (176–504) Pulmonary embolism 93 (48 10 (6–15) 373 (236–565) High resolution 26718 48 (5–12) 303 (176–504) High resolution 12 (36, 33)				
Temporal bone	Low dose			
Ventracular shunt			, ,	
Facial skeltron 74245 21 (14-32) 531 (310-716) Routine dose Stroke 23026 46 (42-53) 891 (778-1066 Head, routine or not otherwise specified 970080 45 (37-55) 851 (688-1048 Tiauma 47412 45 (40-52) 851 (688-1048 High dose Stroke Stroke Stroke Stroke Stroke Derfusion angiography 60101 94 (55-150) 1280 (751-1866 Chest Stroke Strok	•			417 (293–595)
Stroke				
Stroke 23 026 46 (42-53) 891 (778-1066 Head, routine or not otherwise specified 970080 45 (37-55) 851 (688-1048 Trauma 47412 45 (40-52) 851 (761-1085) High dose "Perfusion angiography 60 101 94 (55-150) 1280 (751-1866) Chest "Une cancer screening and nodule surveillance 43 202 2 (2-3) 85 (62-111) Routine dose "Chest, routine or not otherwise specified 492726 8 (5-12) 303 (176-504) Pulmonary embolism 93648 10 (6-15) 373 (236-655) High resolution 26718 9 (6-13) 428 (292-601) Anjography 126363 11 (8-16) 441 (293-712) Interstitial lung disease 2690 7 (4-9) 545 (318-759) Interstitial lung disease 2690 7 (4-9) 545 (318-759) Trauma 9726 15 (10-0) 657 (447-80) 16 (40-80) 82 (56-112) 813 (574-1243) 16 (40-80) 82 (56-112) 80 (56-112) 813 (574-1243) 16 (40-80) 82 (56-112) Routine dose 12 (8-17) <td></td> <td>74 245</td> <td>21 (14–32)</td> <td>531 (310–716)</td>		74 245	21 (14–32)	531 (310–716)
Head, routine or not otherwise specified 970080 45 (37–55) 851 (688–1048 Trauma 47412 45 (40–52) 851 (761–1085 High dose 7761–780 780 (101 94 (50–51) 1280 (751–1866				
Trauma 47 412 45 (40-52) 851 (761-1085 High dose Perfusion angiography 60 101 94 (55-150) 1280 (751-1866 Chest Routine dose Chest Chest Routine or not otherwise specified 492726 8 (5-12) 303 (176-504) Pulmonary embolism 93648 10 (6-15) 373 (236-565) High resolution 26718 9 (6-13) 428 (292-601) Angiography 126363 11 (8-16) 441 (293-712) Interstitial lung disease 2690 7 (4-9) 545 (318-759) Trauma 9726 15 (10-0) 657 (474-980) Lung cancer 1712 2 (2-7) 69 (55-336) High dose Chest				
High dose Perfusion angiography Pulmonary embolism Perfusion angiography Pulmonary embolism Perfusion angiography Pulmonary embolism Perfusion angiography Pulmonary embolism Perfusion angiography Pe	-			
Perfusion angiography Commonsion Comm		47 412	45 (40–52)	851 (761–1085)
Chest Lung cancer screening and nodule surveillance 43 202 2 (2-3) 85 (62-111)	e e e e e e e e e e e e e e e e e e e			
Lung cancer screening and nodule surveillance 43 202 2 (2-3) 85 (62-111)		60 101	94 (55–150)	1280 (751–1866)
Lung cancer screening and nodule surveillance 43 202 2 (2-3) 85 (62-111) Routine dose				
Routine dose		(0.000	2 (2 2)	07//2
Chest, routine or not otherwise specified 492726 8 (5-12) 303 (176-504) Pulmonary embolism 93648 10 (6-15) 373 (236-565) High resolution 26718 9 (6-13) 428 (292-601) Angiography 126363 11 (8-16) 441 (293-712) Interstital lung disease 2690 7 (4-9) 545 (318-759) Trauma 9726 15 (10-0) 657 (474-980) Lung cancer 1712 2 (2-7) 69 (55-336) High dose 395 12 (8-17) 813 (574-1243) Cardiac 397 40-8 82 (56-112) 820 (74-499) Coronary calcification 17164 6 (4-8) 82 (56-112) 82 (56-112) 82 (56-112) 82 (56-112) 82 (56-112) 82 (56-112) 82 (56-112) 82 (56-112)	· ·	43 202	2 (2–3)	85 (62–111)
Pulmonary embolism 93648 10 (6-15) 373 (236-565) High resolution 26718 9 (6-13) 428 (292-601) Angiography 126363 11 (8-16) 441 (293-712) Interstitial lung disease 2690 7 (4-9) 545 (318-759) Trauma 9726 15 (10-0) 657 (474-980) Lung cancer 1712 2 (2-7) 69 (55-336) High dose 1995 12 (8-17) 813 (574-1243) Cardiac 2 2-7 80 (55-336) High dose 17164 6 (4-8) 82 (56-112) Coronary calcification 17164 6 (4-8) 82 (56-112) Routine dose 2 7 (3-16) 220 (74-499) Coronary angiography 26906 13 (7-25) 417 (191, 903) High dose 1 11 (7-20) 1481 (898-2217) Abscess 49 (24) 24 (14-47) 1481 (898-2217) Absces 49 (23) 9 (6-15) 493 (323-797) Bladder (without contrast material) 18 130 11 (7-14)		(02.72)	0 (5 10)	202 (156 52)
High resolution	-			
Angiography 126 363 11 (8-16) 441 (293-712) Interstitial lung disease 2690 7 (4-9) 545 (318-759) Trauma 9726 15 (10-0) 657 (474-980) Lung cancer 1712 2 (2-7) 69 (55-336) High dose Using cancer Dissection 1995 12 (8-17) 813 (574-1243) Cardiac Using calcification 17164 6 (4-8) 82 (56-112) Coronary calcification 17164 6 (4-8) 82 (56-112) Routine dose Cardiac, routine, or not otherwise specified 12125 7 (3-16) 220 (74-499) Coronary angiography 26 906 13 (7-25) 417 (191, 903) High dose Transaortic valvular replacement 4186 24 (14-47) 1481 (898-2217) Abdomen Low dose Colonography 9933 4 (3-5) 429 (298-532) Suspected renal stones 49233 9 (6-15) 493 (323-797) Bladder (without contrast material) 18 130 11 (7-14) <t< td=""><td>•</td><td></td><td></td><td></td></t<>	•			
Interstitial lung disease	•			
Trauma 9726 15 (10-0) 657 (474-980) Lung cancer 1712 2 (2-7) 69 (55-336) High dose 1995 12 (8-17) 813 (574-1243) Cardiac Use of the secondary of the sec			` '	
Lung cancer 1712 2 (2-7) 69 (55-336) High dose Ubisection 1995 12 (8-17) 813 (574-1243) Cardiac Cardiac Low dose Coronary calcification 17 164 6 (4-8) 82 (56-112) Routine dose Cardiac, routine, or not otherwise specified 12125 7 (3-16) 220 (74-499) Coronary angiography 26 906 13 (7-25) 417 (191, 903) High dose Transaortic valvular replacement 4186 24 (14-47) 1481 (898-2217) Abdomen Low dose Colonography 9933 4 (3-5) 429 (298-532) Suspected renal stones 49233 9 (6-15) 493 (323-797) Bladder (without contrast material) 18 130 11 (7-14) 644 (296-760) Routine dose Abscess 302 11 (7-17) 444 (268-766) Abdomen routine, not otherwise specified 884 106 11 (8-17) 640 (412-1022) Gastrointestinal tract evaluation, enterography 29 846 10 (7-15) 517 (354-864) Trauma 19 518 <td< td=""><td>~</td><td></td><td></td><td></td></td<>	~			
High dose Dissection 1995 12 (8–17) 813 (574–1243 Cardiac Low dose Coronary calcification 17164 6 (4–8) 82 (56–112) Routine dose Cardiac, routine, or not otherwise specified 12125 7 (3–16) 220 (74–499) Coronary angiography 26906 13 (7–25) 417 (191, 903) High dose Transaortic valvular replacement 4186 24 (14–47) 1481 (898–2217 Abdomen Low dose Colonography 9933 4 (3–5) 429 (298–532) Suspected renal stones 49233 9 (6–15) 493 (323–797) Bladder (without contrast material) 18130 11 (7–17) 444 (268–760) Routine dose Abscess 302 11 (7–17) 444 (268–760) Abdomen routine, not otherwise specified 884 106 11 (8–17) 640 (412–1022 Gastrointestinal tract evaluation, enterography 29 846 10 (7–15) 517 (354–864) Trauma 19518 15 (10–21) 833 (517–1405 Angiography 19518 15 (10–21) 833 (517–1405 Angiography 1960 10 (7–16) 1151 (600–2007 High dose Adreal nodule 353 12 (9–15) 397 (227–684) Fistula 54 9 (6–13) 615 (464–910) Angiography for aortic injury 18220 7 (4–12) 667 (365–1240 Transplant 2832 7 (6–10) 704 (468–1086 Bladder with contrast 4993 10 (6–15) 1187 (544–2014 Pancreas 9702 11 (8–16) 1151 (544–2017)			` '	
Dissection 1995 12 (8–17) 813 (574–1243	· ·	1/12	2 (2-/)	69 (55–336)
Cardiac Low dose Coronary calcification 17 164 6 (4-8) 82 (56-112) Routine dose Cardiac, routine, or not otherwise specified 12125 7 (3-16) 220 (74-499) Coronary angiography 26 906 13 (7-25) 417 (191, 903) High dose Tansaortic valvular replacement 4186 24 (14-47) 1481 (898-2217 Abdomen Low dose Colonography 9933 4 (3-5) 429 (298-532) Suspected renal stones 49 233 9 (6-15) 493 (323-797) Bladder (without contrast material) 18 130 11 (7-14) 614 (396-790) Routine dose Abscess 302 11 (7-17) 444 (268-766) Abdomen routine, not otherwise specified 884 106 11 (8-17) 640 (412-1022) Gastrointestinal tract evaluation, enterography 29 846 10 (7-15) 517 (354-864) Trauma 19 518 15 (10-21) 833 (517-1405) Angiography 36705 11 (7-15) 1117 (675-1801) Liver, not otherwise specified 25 016 10 (7-16) 1151 (600-2007) High dose Adrenal nodule 353 12 (9-15) 397 (227-684) Fistula 54 9 (6-13) 615 (464-910) Angiography for aortic injury† 8220 7 (4-12) 667 (365-1240) Transplant 2832 7 (6-10) 704 (468-1086) Bladder with contrast 4993 10 (6-15) 1187 (548-2014) Pancreas 9702 11 (8-16) 1171 (753-1777)	· · ·	1005	12 (0, 17)	012 (57/ 12/2
Low dose Coronary calcification 17 164 6 (4–8) 82 (56–112)		1995	12 (8–17)	813 (5/4–1243)
Coronary calcification 17 164 6 (4–8) 82 (56–112) Routine dose Cardiac, routine, or not otherwise specified 12 125 7 (3–16) 220 (74–499) Coronary angiography 26 906 13 (7–25) 417 (191, 903) High dose 34 (14–47) 1481 (898–2217 Abdomen 34 (14–47) 1481 (898–2217 Low dose 35 (20–12) 49 (298–532) Colonography 9933 4 (3–5) 429 (298–532) Suspected renal stones 49 (233) 9 (6–15) 493 (323–797) Bladder (without contrast material) 18 130 11 (7–14) 614 (396–790) Routine dose 302 11 (7–17) 444 (268–766) Abscess 302 11 (7–17) 444 (268–766) Abdomen routine, not otherwise specified 884 106 11 (8–17) 640 (412–1022) Gastrointestinal tract evaluation, enterography 29 846 10 (7–15) 517 (354–864) Trauma 19518 15 (10–21) 833 (517–1405) Angiography 3670 11 (7–15) 117 (675–1801) <td></td> <td></td> <td></td> <td></td>				
Routine dose Cardiac, routine, or not otherwise specified 12125 7 (3–16) 220 (74–499) Coronary angiography 26906 13 (7–25) 417 (191, 903) High dose Transaortic valvular replacement 4186 24 (14–47) 1481 (898–2217 Abdomen Low dose Colonography 9933 4 (3–5) 429 (298–532) Suspected renal stones 49233 9 (6–15) 493 (323–797) Bladder (without contrast material) 18130 11 (7–14) 614 (396–790) Routine dose Abscess 302 11 (7–17) 444 (268–766) Abdomen routine, not otherwise specified 884106 11 (8–17) 640 (412–1022) Gastrointestinal tract evaluation, enterography 29846 10 (7–15) 517 (354–864) Trauma 19518 15 (10–21) 833 (517–1405) Angiography 36705 11 (7–15) 1117 (675–1801) Liver, not otherwise specified 25016 10 (7–16) 1151 (600–2007) High dose Adrenal nodule 353 12 (9–15) 397 (227–684) Fistula 54 9 (6–13) 615 (464–910) Angiography for aortic injury† 8220 7 (4–12) 667 (365–1240) Transplant 2832 7 (6–10) 704 (468–1086) Bladder with contrast 4993 10 (6–15) 1187 (544–2014) Pancreas 9702 11 (8–16) 1171 (753–1777		17164	((4, 9)	02 (5(112)
Cardiac, routine, or not otherwise specified 12125 7 (3–16) 220 (74–499) Coronary angiography 26906 13 (7–25) 417 (191, 903) High dose Transaortic valvular replacement 4186 24 (14–47) 1481 (898–2217 Abdomen Low dose Colonography 9933 4 (3–5) 429 (298–532) Suspected renal stones 49233 9 (6–15) 493 (323–797) Bladder (without contrast material) 18 130 11 (7–14) 614 (396–790) Routine dose Abscess 302 11 (7–17) 444 (268–766) Abdomen routine, not otherwise specified 884 106 11 (8–17) 640 (412–1022) Gastrointestinal tract evaluation, enterography 29 846 10 (7–15) 517 (354–864) Trauma 19518 15 (10–21) 333 (517–1405) Angiography 36705 11 (7–16) 1117 (675–1801) Liver, not otherwise specified 25 016 10 (7–16) 1151 (600–2007) High dose Adrenal nodule 353 12 (9–15) 397 (227–684)	·	1/104	0 (4–8)	82 (30–112)
Coronary angiography 26 906 13 (7-25) 417 (191, 903) High dose Transaortic valvular replacement 4186 24 (14-47) 1481 (898-2217 Abdomen Low dose Colonography 9933 4 (3-5) 429 (298-532) Suspected renal stones 49 233 9 (6-15) 493 (323-797) Bladder (without contrast material) 18 130 11 (7-14) 614 (396-790) Routine dose Abscess 302 11 (7-17) 444 (268-766) Abdomen routine, not otherwise specified 884 106 11 (8-17) 640 (412-1022) Gastrointestinal tract evaluation, enterography 29 846 10 (7-15) 517 (354-864) Trauma 19 518 15 (10-21) 833 (517-1405) Angiography 36705 11 (7-15) 1117 (675-1801) Liver, not otherwise specified 25 016 10 (7-16) 1151 (600-2007) High dose Adrenal nodule 353 12 (9-15) 397 (227-684) Fistula 54 9 (6-13) 615 (464-910) <td< td=""><td></td><td>12 125</td><td>7 (2 16)</td><td>220 (7/, /00)</td></td<>		12 125	7 (2 16)	220 (7/, /00)
High dose Transaortic valvular replacement 4186 24 (14-47) 1481 (898-2217 Abdomen Low dose Colonography 9933 4 (3-5) 429 (298-532) Suspected renal stones 49233 9 (6-15) 493 (323-797) Bladder (without contrast material) 18 130 11 (7-14) 614 (396-790) Routine dose Abscess 302 11 (7-17) 444 (268-766) Abdomen routine, not otherwise specified 884 106 11 (8-17) 640 (412-1022) Gastrointestinal tract evaluation, enterography 29 846 10 (7-15) 517 (354-864) Trauma 19 518 15 (10-21) 833 (517-1405) Angiography 36 705 11 (7-15) 1117 (675-1801) Liver, not otherwise specified 25 016 10 (7-16) 1151 (600-2007) High dose Adrenal nodule 353 12 (9-15) 397 (227-684) Fistula 54 9 (6-13) 615 (464-910) Angiography for aortic injury† 8220 7 (4-12) 667 (365-1240) Transplant 2832 7 (6-10) 704 (468-108	•			
Transaortic valvular replacement 4186 24 (14-47) 1481 (898-2217) Abdomen Low dose Colonography 9933 4 (3-5) 429 (298-532) Suspected renal stones 49 233 9 (6-15) 493 (323-797) Bladder (without contrast material) 18 130 11 (7-14) 614 (396-790) Routine dose 302 11 (7-17) 444 (268-766) Abdomen routine, not otherwise specified 884 106 11 (8-17) 640 (412-1022) Gastrointestinal tract evaluation, enterography 29 846 10 (7-15) 517 (354-864) Trauma 19 518 15 (10-21) 833 (517-1405) Angiography 36 705 11 (7-15) 1117 (675-1801) Liver, not otherwise specified 25 016 10 (7-16) 1151 (600-2007) High dose 4Adrenal nodule 353 12 (9-15) 397 (227-684) Fistula 54 9 (6-13) 615 (464-910) Angiography for aortic injury† 8220 7 (4-12) 667 (365-1240) Transplant 2832 7 (6-10) 704 (468-1086) Bladder with contrast 4993 10 (6-15)	, , , ,	20 900	13 (/=23)	41/ (191, 903)
Abdomen Low dose Colonography 9933 4 (3–5) 429 (298–532) Suspected renal stones 49 233 9 (6–15) 493 (323–797) Bladder (without contrast material) 18 130 11 (7–14) 614 (396–790) Routine dose Abscess 302 11 (7–17) 444 (268–766) Abdomen routine, not otherwise specified 884 106 11 (8–17) 640 (412–1022) Gastrointestinal tract evaluation, enterography 29 846 10 (7–15) 517 (354–864) Trauma 19518 15 (10–21) 833 (517–1405) Angiography 36705 11 (7–15) 1117 (675–1801) Liver, not otherwise specified 25 016 10 (7–16) 1151 (600–2007) High dose Adrenal nodule 353 12 (9–15) 397 (227–684) Fistula 54 9 (6–13) 615 (464–910) Angiography for aortic injury† 8220 7 (4–12) 667 (365–1240) Transplant 2832 7 (6–10) 704 (468–1086) Bladder with contrast 4993 10 (6–15) 1187 (544–2014) Pancreas 9702 11 (8–16) 1171 (753–1777)		4196	24 (14, 47)	1/01/000 2217
Colonography 9933 4 (3–5) 429 (298–532) Suspected renal stones 49 233 9 (6–15) 493 (323–797) Bladder (without contrast material) 18 130 11 (7–14) 614 (396–790) Routine dose		4180	24 (14–4/)	1401 (070–2217)
Colonography 9933 4 (3-5) 429 (298-532) Suspected renal stones 49 233 9 (6-15) 493 (323-797) Bladder (without contrast material) 18 130 11 (7-14) 614 (396-790) Routine dose 302 11 (7-17) 444 (268-766) Abdomen routine, not otherwise specified 884 106 11 (8-17) 640 (412-1022) Gastrointestinal tract evaluation, enterography 29 846 10 (7-15) 517 (354-864) Trauma 19518 15 (10-21) 833 (517-1405) Angiography 36705 11 (7-15) 1117 (675-1801) Liver, not otherwise specified 25 016 10 (7-16) 1151 (600-2007) High dose 353 12 (9-15) 397 (227-684) Fistula 54 9 (6-13) 615 (464-910) Angiography for aortic injury† 8220 7 (4-12) 667 (365-1240) Transplant 2832 7 (6-10) 704 (468-1086) Bladder with contrast 4993 10 (6-15) 1187 (544-2014) Pancreas 9702 11 (8-16) 1171				
Suspected renal stones 49 233 9 (6-15) 493 (323-797) Bladder (without contrast material) 18 130 11 (7-14) 614 (396-790) Routine dose Abscess 302 11 (7-17) 444 (268-766) Abdomen routine, not otherwise specified 884 106 11 (8-17) 640 (412-1022) Gastrointestinal tract evaluation, enterography 29 846 10 (7-15) 517 (354-864) Trauma 19518 15 (10-21) 833 (517-1405) Angiography 36705 11 (7-15) 1117 (675-1801) Liver, not otherwise specified 25 016 10 (7-16) 1151 (600-2007) High dose Adrenal nodule 353 12 (9-15) 397 (227-684) Fistula 54 9 (6-13) 615 (464-910) Angiography for aortic injury† 8220 7 (4-12) 667 (365-1240) Transplant 2832 7 (6-10) 704 (468-1086) Bladder with contrast 4993 10 (6-15) 1187 (544-2014) Pancreas 9702 11 (8-16) 1171 (753-1777)		9933	4 (3_5)	429 (298_532)
Bladder (without contrast material) 18 130 11 (7-14) 614 (396-790) Routine dose 302 11 (7-17) 444 (268-766) Abscess 302 11 (7-17) 444 (268-766) Abdomen routine, not otherwise specified 884 106 11 (8-17) 640 (412-1022) Gastrointestinal tract evaluation, enterography 29 846 10 (7-15) 517 (354-864) Trauma 19 518 15 (10-21) 833 (517-1405) Angiography 36705 11 (7-15) 1117 (675-1801) Liver, not otherwise specified 25 016 10 (7-16) 1151 (600-2007) High dose Adrenal nodule 353 12 (9-15) 397 (227-684) Fistula 54 9 (6-13) 615 (464-910) Angiography for aortic injury† 8220 7 (4-12) 667 (365-1240) Transplant 2832 7 (6-10) 704 (468-1086) Bladder with contrast 4993 10 (6-15) 1187 (544-2014) Pancreas 9702 11 (8-16) 1171 (753-1777)				
Routine dose Abscess 302 11 (7-17) 444 (268-766) Abdomen routine, not otherwise specified 884 106 11 (8-17) 640 (412-1022) Gastrointestinal tract evaluation, enterography 29 846 10 (7-15) 517 (354-864) Trauma 19518 15 (10-21) 833 (517-1405) Angiography 36705 11 (7-15) 1117 (675-1801) Liver, not otherwise specified 25 016 10 (7-16) 1151 (600-2007) High dose Adrenal nodule 353 12 (9-15) 397 (227-684) Fistula 54 9 (6-13) 615 (464-910) Angiography for aortic injury† 8220 7 (4-12) 667 (365-1240) Transplant 2832 7 (6-10) 704 (468-1086) Bladder with contrast 4993 10 (6-15) 1187 (544-2014) Pancreas 9702 11 (8-16) 1171 (753-1777)				
Abscess 302 11 (7-17) 444 (268-766) Abdomen routine, not otherwise specified 884 106 11 (8-17) 640 (412-1022) Gastrointestinal tract evaluation, enterography 29 846 10 (7-15) 517 (354-864) Trauma 19518 15 (10-21) 833 (517-1405) Angiography 36705 11 (7-15) 1117 (675-1801) Liver, not otherwise specified 25 016 10 (7-16) 1151 (600-2007) High dose Adrenal nodule 353 12 (9-15) 397 (227-684) Fistula 54 9 (6-13) 615 (464-910) Angiography for aortic injury† 8220 7 (4-12) 667 (365-1240) Transplant 2832 7 (6-10) 704 (468-1086) Bladder with contrast 4993 10 (6-15) 1187 (544-2014) Pancreas 9702 11 (8-16) 1171 (753-1777)		101,00	11 (/-14)	014 (370–770)
Abdomen routine, not otherwise specified 884 106 11 (8–17) 640 (412–1022 Gastrointestinal tract evaluation, enterography 29 846 10 (7–15) 517 (354–864) Trauma 19518 15 (10–21) 833 (517–1405 Angiography 36705 11 (7–15) 1117 (675–1801 Liver, not otherwise specified 25 016 10 (7–16) 1151 (600–2007 High dose Adrenal nodule 353 12 (9–15) 397 (227–684) Fistula 54 9 (6–13) 615 (464–910) Angiography for aortic injury† 8220 7 (4–12) 667 (365–1240 Transplant 2832 7 (6–10) 704 (468–1086 Bladder with contrast 4993 10 (6–15) 1187 (544–2014 Pancreas 9702 11 (8–16) 1171 (753–1777		302	11 (7_17)	444 (268_766)
Gastrointestinal tract evaluation, enterography 29 846 10 (7-15) 517 (354-864) Trauma 19 518 15 (10-21) 833 (517-1405) Angiography 36 705 11 (7-15) 1117 (675-1801) Liver, not otherwise specified 25 016 10 (7-16) 1151 (600-2007) High dose Adrenal nodule 353 12 (9-15) 397 (227-684) Fistula 54 9 (6-13) 615 (464-910) Angiography for aortic injury† 8220 7 (4-12) 667 (365-1240) Transplant 2832 7 (6-10) 704 (468-1086) Bladder with contrast 4993 10 (6-15) 1187 (544-2014) Pancreas 9702 11 (8-16) 1171 (753-1777)				
Trauma 19518 15 (10–21) 833 (517–1405) Angiography 36705 11 (7–15) 1117 (675–1801) Liver, not otherwise specified 25 016 10 (7–16) 1151 (600–2007) High dose	•			
Angiography 36705 11 (7–15) 1117 (675–1801 Liver, not otherwise specified 25 016 10 (7–16) 1151 (600–2007 High dose Adrenal nodule 353 12 (9–15) 397 (227–684) Fistula 54 9 (6–13) 615 (464–910) Angiography for aortic injury† 8220 7 (4–12) 667 (365–1240 Transplant 2832 7 (6–10) 704 (468–1086 Bladder with contrast 4993 10 (6–15) 1187 (544–2014 Pancreas 9702 11 (8–16) 1171 (753–1777				
Liver, not otherwise specified 25 016 10 (7-16) 1151 (600-2007) High dose Adrenal nodule 353 12 (9-15) 397 (227-684) Fistula 54 9 (6-13) 615 (464-910) Angiography for aortic injury† 8220 7 (4-12) 667 (365-1240) Transplant 2832 7 (6-10) 704 (468-1086) Bladder with contrast 4993 10 (6-15) 1187 (544-2014) Pancreas 9702 11 (8-16) 1171 (753-1777)				
High dose Adrenal nodule 353 12 (9–15) 397 (227–684) Fistula 54 9 (6–13) 615 (464–910) Angiography for aortic injury† 8220 7 (4–12) 667 (365–1240) Transplant 2832 7 (6–10) 704 (468–1086) Bladder with contrast 4993 10 (6–15) 1187 (544–2014) Pancreas 9702 11 (8–16) 1171 (753–1777)				
Adrenal nodule 353 12 (9-15) 397 (227-684) Fistula 54 9 (6-13) 615 (464-910) Angiography for aortic injury† 8220 7 (4-12) 667 (365-1240 Transplant 2832 7 (6-10) 704 (468-1086 Bladder with contrast 4993 10 (6-15) 1187 (544-2014 Pancreas 9702 11 (8-16) 1171 (753-1777		27010	10 (/ 10)	11)1 (000-200)
Fistula 54 9 (6–13) 615 (464–910) Angiography for aortic injury† 8220 7 (4–12) 667 (365–1240) Transplant 2832 7 (6–10) 704 (468–1086) Bladder with contrast 4993 10 (6–15) 1187 (544–2014) Pancreas 9702 11 (8–16) 1171 (753–1777)		353	12 (9–15)	397 (227–684)
Angiography for aortic injury [†] 8220 7 (4–12) 667 (365–1240 Transplant 2832 7 (6–10) 704 (468–1086 Bladder with contrast 4993 10 (6–15) 1187 (544–2014 Pancreas 9702 11 (8–16) 1171 (753–1777				
Transplant 2832 7 (6–10) 704 (468–1086 Bladder with contrast 4993 10 (6–15) 1187 (544–2014 Pancreas 9702 11 (8–16) 1171 (753–1777				
Bladder with contrast 4993 10 (6–15) 1187 (544–2014 Pancreas 9702 11 (8–16) 1171 (753–1777				
Pancreas 9702 11 (8–16) 1171 (753–1777	•			
	Diadder with contrast	-//5		
		9702	11 (8–16)	1171 (753_1777

Table 4: (continued) Median, 25th, and 75th Percentiles of DLP and CTDI of Fach Cl	linical Indication for Head, Chest, Cardiac,
Abdomen, and Combined Head and Neck Body Regions	

CT Category and Indication	No. of Examinations	CTDI _{vol} *	DLP*
Metastatic cancers	2827	15 (10–20)	1074 (811–1411)
Urography	32 287	11 (8–16)	1144 (710–1817)
Acute gastrointestinal bleeding	3560	10 (7–15)	1310 (834–2060)
Abdominal run-off	10 025	8 (6–11)	1386 (991–2147)
Renal mass	9436	14 (10–19)	1633 (1069–2337)
Combined head and neck			
Routine dose			
Routine dose head combined with any neck and/or cervical spine	88 106	21 (14–32)	957 (580–1309)
High dose			
High dose head combined with any neck and/or cervical spine	10078	145 (99–262)	2547 (1676–3646)

Note.—CTDI_{vol} = volume CT dose index, DLP = dose-length product.

[†] Angiography for aortic injury includes rupture, dissection, and endovascular leak.




Figure 2: Graphs show volume CT dose index (CTDI_{vol}) and dose-length product (DLP) for each indication that comprises (A) head, (B) chest, (C) abdomen, and (D) cardiac CT categories. Length of arms in cross show interquartile range in radiation dose. Intersection of arms is median for CTDI_{vol} and DLP, number of lines reflects number of indications in category, and line thickness is proportional to number of examinations in category. For each indication, CTDI_{vol} is defined as mean CTDI_{vol} across all irradiating events weighted by scanning length, and DLP value is summation across all irradiating events. For example, in three-phase study, where each phase (ie, irradiating event) had average CTDI_{vol} of 10 mGy, scanning length of 50 cm, and DLP of 500 mGy · cm, study would be shown in plot as average weighted CTDI_{vol} of 10 mGy and total DLP of 1500 mGy · cm.

dose chest (753583 examinations), and routine dose abdomen (1002264 examinations)—accounted for 62% of all CT examinations. Given this frequency, optimizing acquisition protocols in these three categories alone could have a substantial impact on reducing overall radiation exposure from CT examinations.

For the purpose of comparing radiation doses across facilities, assessing doses within broad CT categories based on clinical indication is more informative than assessing doses within protocols. Dose assessment within protocol groups ignores the primary factor determining dose (ie, protocol selection), which is almost entirely at the discretion of the radiologist. Assessing doses in this way, without considering the underlying indication, ignores the variation that occurs due to protocol choice and fails to identify patients who require a particular protocol, such as single-phase abdomen, but who instead received much higher doses through unnecessary multiphase examinations. Radiation doses should be assessed based on the intent and clinical question of the provider ordering the examination, not on the radiologist's choice of protocol.

The data for this study were pulled from the University of California San Francisco registry, but other data sources, such as the larger American College of Radiology Dose Index Regis-

try, could be used to similarly categorize CT examinations based on the indications that led to the examinations and then to create radiation dose benchmarks for those categories (12). Because the existing American College of Radiology benchmarks are created according to protocol (1), rather than according to clinical

^{*} Numbers are medians, with interquartile ranges (25th and 75th percentiles) in parentheses.

Table 5: Variation within Indications versus between Indications for CT Categories and within Categories versus between Categories within Body Regions

	Variation between Indications within CT Category					Variation between CT Categories				
Location and Dose	Mean Square within Indications	Mean Square between Indication within CT Category	Between versus Within (F value)	Ratio of F Value to N	Mean Square within CT Category	Mean Square between CT Categories within Body Region	Between versus Within (F value)	Ratio of F Value to N		
Head					175 236	16976982486	96881	0.10		
Low dose	142 076	633 014 914	4455	0.04						
Routine dose	121 079	127 912 884	1056	0.00						
High dose*	NC	NC	NC	NC						
Chest					161 216	2 4 5 1 4 4 3 5 0 5	15 206	0.02		
Low dose*	NC	NC	NC	NC						
Routine dose	162 960	618 213 847	3794	0.01						
High dose*	NC	NC	NC	NC						
Abdomen					308 649	14 395 193 179	46 639	0.05		
Low dose	107 303	54 353 482	507	0.01						
Routine dose	260 005	1 082 879 111	4165	0.00						
High dose	738 482	385 328 496	522	0.01						
Cardiac					316698	3 9 9 7 8 5 1 4 6 8	13342	0.26		
Low dose*	NC	NC	NC	NC						
Routine dose	315 257	482 266 188	1530	0.05						
High dose*	NC	NC	NC	NC						

Note.—P < .001 for all statistical comparisons. N = number of examinations, NC = not calculated.

indication as described herein, it is not possible to directly compare observed doses. However, given the similarity in how CT examinations are assembled in the University of California San Francisco and American College of Radiology registries, it would be worthwhile to compare benchmarks based on indications across the registries.

For some CT categories, the observed doses reflect optimized levels. For example, the median CTDI of for low dose chest is 2 mGy, consistent with the American College of Radiology benchmarks (16). For other categories, the observed doses are not optimized. For example, for abdomen low dose, where 64% of examinations assessed renal calculi, the median in CTDI was 9 mGy, higher than the optimum of less than 4 mGy (17). The consistency in doses for CT examinations performed for lung cancer screening with American College of Radiology benchmarks may be driven by the fact that reporting is required by the Centers for Medicare and Medicaid Services for reimbursement. The inconsistency in doses for suspected renal stone imaging is consistent with previously reported deviation between observed and optimum practice (9,18). Although the proposed framework does not provide optimized dose levels because actual practice is often not optimized, adoption of this simplified approach for assessing radiation doses may nevertheless contribute to dose improvement over time by allowing consistent measurement of current practice.

A potential application of the framework is in meeting standards of regulators and accreditors. For example, the Joint Commission requires that hospitals ensure patients receive appropriate imaging based on their clinical indication for scanning and review of incidents in which the radiation dose delivered exceeds the expected dose for that protocol (19). This standard requires hospitals to have a system to both assign patients to protocols and to generate radiation dose thresholds for each protocol; however, there is no consistent standard used across hospitals. We believe that our approach could provide a simpler and more effective solution for comparing radiation doses across institutions, leading to dose optimization and ultimately a reduction in excessively high radiation doses.

This study's main strengths include its large sample size and inclusion of the majority of CT examinations from diverse imaging facilities. The study had several limitations. First, a large number of CT examinations in the registry were for "routine" purposes and where indication was not specified. However, because our primary aim was to identify examinations that required radiation doses that were not routine (ie, high or low), the inability to identify a precise indication for examinations considered routine does not undermine the approach. If there were multiple clinical indications for CT, the examination was assigned to the higher dose category. Although this may have added imprecision, excluding such examinations would have inflated the differences between groups; thus, their inclusion was conservative.

Nearly all diagnostic CT examinations in the present study can be assigned to one of the identified categories. Nonetheless, facilities may need to create additional protocols if they have patients with unique needs not captured in the indications that

^{*} Each of these CT categories had only one indication; thus, these values were NC.

we observed. The categories were created in part based on expert opinion and face validity rather than on evidence associated with diagnostic accuracy; thus, additional research is needed to determine the minimum required image quality for diagnostic accuracy for each indication. As the framework is applied, refinements might include combining or subdividing some of the 19 categories. The assignment of examinations to the CT categories based on Digital Imaging and Communications in Medicine metadata has inaccuracies; 408 176 examinations (approximately 10%) were misclassified in our assessment. The accuracy of assigning examinations to CT categories based on clinical indication may be improved using information extracted from the electronic health record associated with the study order. Finally, sites contributing to the registry use a single-dose management software, which could introduce bias if sites that use such monitoring programs pay closer attention to radiation use.

Based on the large data set of the University of California San Francisco International CT Dose Registry, we established a framework to assess radiation doses. These categories may offer imaging facilities a consistent, simplified approach to radiation dose assessment, optimization, and reduction of unintended harm.

Author contributions: Guarantor of integrity of entire study, R.S.B.; study concepts/study design or data acquisition or data analysis/interpretation, all authors; manuscript drafting or manuscript revision for important intellectual content, all authors; approval of final version of submitted manuscript, all authors; agrees to ensure any questions related to the work are appropriately resolved, all authors; iterature research, R.S.B., S.Y., B.B., A.J.E.; clinical studies, R.S.B., A.A.C., B.D., A.J.E., A.C.W.; statistical analysis, R.S.B., S.Y., Y.W., P.C., R.C., J.L.; and manuscript editing, R.S.B., S.Y., Y.W., M.D.K., R.C., D.B., C.S., B.B., A.A.C., B.D., A.J.E., M.F., P.R., J.A.S., A.C.W., A.B.

Disclosures of Conflicts of Interest: R.S.B. Founder of Alara Imaging. S.Y. No relevant relationships. Y.W. No relevant relationships. M.D.K. Chair of the board of directors for the Society for Imaging Informatics in Medicine; consultant for Alara Imaging; payment for lectures, including service on speakers bureaus, from Gilead, Honor Health, and SGCR Wires; stock/stock options in Alara Imaging; reimbursement from RSNA, Society for Imaging Informatics in Medicine, DyPatil, and Honor Health for travel, accommodations, and meeting expenses. P.C. No relevant relationships. R.C. Consultant for United Nations Population Division; employee of University of California Berkeley; payment for development of educational presentations from Haute Etudes en Demographie. J.L. No relevant relationships. D.B. No relevant relationships. C.S. No relevant relationships. B.B. No relevant relationships. A.A.C. No relevant relationships. B.D. No relevant relationships. A.J.E. Consultant for W.L. Gore and Associates; grants/grants pending with GE Healthcare and W.L. Gore and Associates; payment for lectures, including service on speakers bureaus, from Ponteix. M.F. No relevant relationships. P.R. No relevant relationships. J.A.S. Employee of University of California Davis; royalties for Essential Physics of Medical Imaging (fourth edition). A.C.W. Stock/stock options in Bot Image. A.B. Stock/stock options in Alara Imaging.

References

 Kanal KM, Butler PF, Sengupta D, Bhargavan-Chatfield M, Coombs LP, Morin RLUS. U.S. Diagnostic Reference Levels and Achievable Doses for 10 Adult CT Examinations. Radiology 2017;284(1):120–133.

- Smith-Bindman R, Wang Y, Chu P, et al. International variation in radiation dose for computed tomography examinations: prospective cohort study. BMJ 2019;364:k4931.
- Guite KM, Hinshaw JL, Ranallo FN, Lindstrom MJ, Lee FT Jr. Ionizing radiation in abdominal CT: unindicated multiphase scans are an important source of medically unnecessary exposure. J Am Coll Radiol 2011;8(11):756–761.
- 4. Szczykutowicz TP. The CT Handbook: Optimizing Protocols for Today's Feature-Rich Scanners. Madison, Wis: MMP Medical Physics Publishing, 2020.
- Szczykutowicz TP, Bour RK, Rubert N, Wendt G, Pozniak M, Ranallo FN. CT protocol management: simplifying the process by using a master protocol concept. J Appl Clin Med Phys 2015;16(4):228–243.
- Sachs PB, Hunt K, Mansoubi F, Borgstede J. CT and MR Protocol Standardization Across a Large Health System: Providing a Consistent Radiologist, Patient, and Referring Provider Experience. J Digit Imaging 2017;30(1):11–16.
- Zhang D, Savage CA, Li X, Liu B. Data-driven CT protocol review and management—experience from a large academic hospital. J Am Coll Radiol 2015;12(3):267–272.
- National Council on Radiation Protection. NCRP Report No. 184: Medical Radiation Exposure of Patients in the United States. Bethesda, Md: National Council on Radiation Protection, 2019.
- Lukasiewicz A, Bhargavan-Chatfield M, Coombs L, et al. Radiation dose index of renal colic protocol CT studies in the United States: a report from the American College of Radiology National Radiology Data Registry. Radiology 2014;271(2):445–451.
- Board of Radiation Effects Research Division on Earth and Life Sciences, National Research Council of the National Academies. Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. Washington, DC: The National Academies Press, 2006.
- Hricak H, Brenner DJ, Adelstein SJ, et al. Managing radiation use in medical imaging: a multifaceted challenge. Radiology 2011;258(3):889–905.
- American College of Radiology. Dose Index Registry. https://www.acr. org/Practice-Management-Quality-Informatics/Registries/Dose-Index-Registry. Accessed August 5, 2021.
- Smith-Bindman R, Chu P, Wang Y, et al. Comparison of the Effectiveness of Single-Component and Multicomponent Interventions for Reducing Radiation Doses in Patients Undergoing Computed Tomography: A Randomized Clinical Trial. JAMA Intern Med 2020;180(5):666–675.
- Image Quality in CT: Defining and Rewarding Computed Tomography Quality and Safety. Cooperative Agreement with the Centers for Medicare and Medicaid Services. https://ctqualitymeasure.ucsf.edu/. Accessed August 5, 2021.
- McCollough C, Bakalyar DM, Bostani M, et al. Use of Water Equivalent Diameter for Calculating Patient Size and Size-Specific Dose Estimates (SSDE) in CT: The Report of AAPM Task Group 220. AAPM Rep 2014-2014-6-23
- Kazerooni EA, Austin JH, Black WC, et al. ACR-STR practice parameter for the performance and reporting of lung cancer screening thoracic computed tomography (CT): 2014 (Resolution 4). J Thorac Imaging 2014;29(5):310–316.
- 17. American College of Radiology. ACR Appropriateness Criteria for the clinical condition for acute onset flank pain, suspicion of stone disease. https://acsearch.acr.org/docs/69362/narrative. Published 1995. Last review date 2015. Accessed October 27, 2021.
- Smith-Bindman R, Moghadassi M, Griffey RT, et al. Computed Tomography Radiation Dose in Patients With Suspected Urolithiasis. JAMA Intern Med 2015;175(8):1413–1416.
- The Joint Commission. Diagnostic Imaging Requirements. https://www. jointcommission.org/-/media/tjc/documents/resources/patient-safety-topics/sentinel-event/sea_47_radiation_revised2_feb_20181.pdf. Issued 2011. Revised 2019. Accessed October 28, 2021.